Revenue
2022
2023
2024
2025
Cognition Therapeutics Inc (CGTX)
Price$1.03Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — |
| Research & development | $37.2M | $41.7M | $37.2M | $30.3M | $18.6M | $12.9M |
| Operating expenses | $47.8M | $54.0M | $50.7M | $43.6M | $28.6M | $17.4M |
| Operating income | −$47.8M | −$54.0M | −$50.7M | −$43.6M | −$28.6M | −$17.4M |
| EBITDA | −$47.8M | −$53.9M | −$50.6M | −$43.5M | −$28.5M | −$17.3M |
| Net income | −$23.5M | −$34.0M | −$25.8M | −$21.4M | −$11.7M | −$7.8M |
| Basic EPSper basic share | -$0.32 | -$0.86 | -$0.86 | -$0.91 | -$3.13 | -$23.76 |
| Diluted EPSper diluted share | -$0.32 | -$0.86 | -$0.86 | -$0.91 | -$3.13 | -$23.76 |
Owners
Reported shareholders
≈6.37%of listed shares
Fletcher Aaron G.L.6.06M shares · Sep 19, 2025
View holders
| Holder | % owned |
|---|---|
Fletcher Aaron G.L. | ≈6.37%6.06M shares |
BIOS Fund III, LP / BIOS Fund III QP, LP / Cavu Advisors, LLC / BIOS Memory SPV II, LP / BIOS Fund II NT, LP / BIOS Fund III NT, LP / BIOS Equity Partners III, LP / Kreis Leslie W. / Cavu Management, LP / BP Directors, LP | ≈6.36%6.05M shares |
BIOS Capital Management, LP | 6.31%6M shares |
DAVENPORT & Co LLC | 4.48%4.26M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.62%3.44M shares |
Ricciardi Lisa | ≈1.85%1.75M shares |
BlackRock, Inc. | 1.33%1.26M shares |
Chescapmanager LLC | 1.05%997.03K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.96%910.01K shares |
Caggiano Anthony | ≈0.92%874.91K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.73%693.29K shares |
Doyle John Brendan | ≈0.65%618.94K shares |
Hilton Capital Management, LLC | 0.58%548.95K shares |
VANGUARD FIDUCIARY TRUST CO | 0.53%508.22K shares |
CM Management, LLC | 0.47%450K shares |
Dauntless Investment Group, LLC | 0.39%371.7K shares |
Sigma Planning Corp | 0.38%362.27K shares |
STATE STREET CORP | 0.37%348.98K shares |
TOCQUEVILLE ASSET MANAGEMENT L.P. | 0.34%320.5K shares |
UBS Group AG | 0.23%218.54K shares |
Percentages use 95.06M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 16, 2026Form 4 | Doyle John BrendanChief Financial Officer | BuyCommon Stock | 10.0K | $1.13 | $11.3K | 627.5K |
| Apr 16, 2026Form 4 | Ricciardi LisaCEO & President | BuyCommon Stock | 9.2K | $1.10 | $10.1K | 1.72M |
| Apr 16, 2026Form 4 | Caggiano AnthonyChief Medical Officer | BuyCommon Stock | 10.0K | $1.11 | $11.1K | 874.9K |
| Jan 31, 2025Form 4 | Ricciardi LisaCEO & President | BuyCommon Stock · indirect | 38.9K | $0.77 | $29.9K | 38.9K |